Breaking The Hospital Chain: Analyst On How KORU's Self-Administered Therapies Promise 20% CAGR Through 2026
Portfolio Pulse from Vandana Singh
B. Riley has initiated coverage of KORU Medical Systems Inc (NASDAQ:KRMD) with a Buy rating and a price target of $4.50. The company's Freedom Infusion System, which allows patients to self-administer subcutaneous immunoglobulin (SCIg) therapy, is expected to drive a 20% compound annual growth rate in its top-line revenue through 2026. The system is poised to tap into a market opportunity exceeding $2 billion.
September 07, 2023 | 6:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
KORU Medical Systems' innovative self-administered therapy system is expected to drive a 20% compound annual growth rate in its top-line revenue through 2026, according to B. Riley. The firm has initiated coverage of the company with a Buy rating and a price target of $4.50.
The positive coverage from B. Riley, along with the promising growth prospects of KORU Medical Systems' Freedom Infusion System, are likely to have a positive impact on the company's stock in the short term. The system's potential to tap into a market opportunity exceeding $2 billion further supports this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100